NINDS CREATE DISCOVERY: Development of dendrimer-N-acetylcysteine for the treatment of neonatal brain injury
NINDS 创造发现:开发用于治疗新生儿脑损伤的树枝状聚合物-N-乙酰半胱氨酸
基本信息
- 批准号:9906957
- 负责人:
- 金额:$ 75.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-03-15 至 2022-02-28
- 项目状态:已结题
- 来源:
- 关键词:AcetylcysteineAddressAdrenoleukodystrophyAdultAdverse drug effectAffectAgeAnimal ModelAnti-Inflammatory AgentsAnxietyAsphyxia NeonatorumAstrocytesAttenuatedBlood - brain barrier anatomyBrainBrain Hypoxia-IschemiaBrain InjuriesCellsCerebral PalsyCerebrumChildChildhoodChildhood Neurological DisorderChronicClinical DataClinical TrialsCyclic GMPCysteineDataDendrimersDevelopmentDevelopmental DisabilitiesDiffuseDoseDrug KineticsEffectivenessEtiologyFemaleGoalsHealth Care CostsHippocampus (Brain)Hydroxyl RadicalImmuneInfantInflammationInjuryInterventionLeadLearningLifeLigandsMagnetic Resonance ImagingManufacturer NameMediatingMemoryMicrogliaMissionModelingMotorMusNanotechnologyNational Institute of Neurological Disorders and StrokeNeonatal Brain InjuryNeurocognitive DeficitNeurodevelopmental DisorderNeurogliaNeurologicNeuronal InjuryNormal RangeOrphanOryctolagus cuniculusOxidative StressPatientsPerinatalPerinatal anoxic ischemic brain injuryPharmaceutical PreparationsPhasePre-Clinical ModelPremature BirthProcessProductionPublic HealthRegimenReproducibilityResearchRewarmingSchemeSepsisSerumStructureTestingTherapeuticTimeTimeLineUnited States National Institutes of HealthWorkbaseclinically relevantcomorbiditydelivery complicationsdisabilityfetalimprovedimproved outcomeindexingintravenous administrationmalemyelinationnatural hypothermianeonatal hypoxic-ischemic brain injuryneonateneuroinflammationneuronal growthneuroprotectionnovelnovel therapeuticspre-clinicalscale upstandard of caretherapy developmentuptake
项目摘要
Project Summary
Cerebral palsy is one of the common chronic childhood neurological disorders and has no effective cure. Half a
million children under the age of 18 in the US have CP, and 1 in 6 children have some form of developmental
disability. Perinatal hypoxic-ischemic encephalopathy (HIE) and maternal-fetal inflammation/immune
dysregulation are major causes of cerebral palsy and related disabilities. Although the collective evidence from
at least 6-large clinical trials confirms that therapeutic hypothermia improves outcome, 40%-50% of infants
treated with hypothermia still die or suffer significant neurologic disability. There remains a critical need for
development of therapies for patients who do not qualify for hypothermia, and for adjunct therapies with
hypothermia that improve neuroprotection and address the negative effects of hypothermia and rewarming.
This is the goal of this 3½ year NINDS CREATE DISCOVERY project.
Recent studies suggest that attenuating neuroinflammation, mediated by activated glia, in the early
stages can not only delay the onset, but may also provide a longer therapeutic window for treatment. However,
delivering drugs across the blood-brain-barrier to target and treat diffuse neuroinflammation is a major
challenge. Our team discovered that systemically-administered hydroxyl-terminated poly(amidoamine)
(PAMAM) dendrimers (~4 nm) target activated glia in the injured brain, without the need for targeting ligands.
Interestingly, intravenous administration of the anti-inflammatory drug N-acetyl cysteine (NAC) conjugated to
the dendrimer (D-NAC), in clinically-relevant preclinical models of CP, resulted in striking neuroprotective
effects. Building on our strong proof-of concept data using our lead compound D-NAC, we propose to optimize
this compound further for use in perinatal/neonatal brain injury, during the discovery phase of the CREATE
application, for progressing towards an eventual developmental phase and clinical trials. Three aims are
identified, along with appropriate milestones: (1) Optimize the synthesis of D-NAC for scale up production, and
demonstrate reproducibility, purity and storage stability. (2) Determine pharmacokinetics, PK-PD relationship,
minimal effective dose, optimal dose and elimination of D-NAC in rabbit model of cerebral palsy. (3) Determine
long term efficacy of D-NAC at the optimal dose identified in Aim 2, in rabbit model of maternal inflammation
induced CP and in term mouse hypoxic-ischemia model with hypothermia.
项目摘要
脑性瘫痪是儿童常见的慢性神经系统疾病之一,目前尚无有效的治疗方法。半个
在美国,18岁以下的儿童有100万人患有CP,每6个儿童中就有1个患有某种形式的发育障碍。
残疾。围产期缺氧缺血性脑病与母儿炎症/免疫
神经失调是脑瘫和相关残疾的主要原因。尽管来自
至少6项大型临床试验证实,治疗性低温可改善预后,40%-50%的婴儿
低温治疗仍然死亡或遭受严重的神经功能障碍。仍然迫切需要
为不符合低温治疗条件的患者开发治疗方法,
降低体温,改善神经保护并解决降低体温和复温的负面影响。
这是为期三年半的NINDS创建发现项目的目标。
最近的研究表明,减轻神经炎症,介导的活化胶质细胞,在早期,
分期不仅可以延迟发作,而且还可以提供更长的治疗窗口。然而,在这方面,
通过血脑屏障递送药物以靶向和治疗弥漫性神经炎症是一个主要的
挑战.我们的团队发现,系统性给药羟基封端的聚(酰胺胺)
(PAMAM)树枝状聚合物(~4 nm)靶向损伤脑中的活化神经胶质,而不需要靶向配体。
有趣的是,静脉内给予与人前列腺素B1结合的抗炎药物N-乙酰半胱氨酸(NAC),
树枝状聚合物(D-NAC),在临床相关的临床前模型的CP,导致显着的神经保护,
方面的影响.基于我们强大的概念验证数据,使用我们的先导化合物D-NAC,我们建议优化
该化合物还用于在CREATE的发现阶段期间的围产期/新生儿脑损伤,
应用,以推进最终的开发阶段和临床试验。三个目标是
沿着适当的里程碑:(1)优化D-NAC的合成以扩大生产,和
证明重现性、纯度和储存稳定性。(2)确定药代动力学、PK-PD关系,
D-NAC在兔脑性瘫痪模型中的最小有效剂量、最佳剂量和消除。(3)确定
目的2中确定的最佳剂量的D-NAC在母体炎症兔模型中的长期疗效
诱导CP和低温致小鼠缺氧缺血模型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sujatha Kannan其他文献
Sujatha Kannan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sujatha Kannan', 18)}}的其他基金
Translational Technologies for Ameliorating Brain Injury
改善脑损伤的转化技术
- 批准号:
10224681 - 财政年份:2018
- 资助金额:
$ 75.02万 - 项目类别:
Translational Technologies for Ameliorating Brain Injury
改善脑损伤的转化技术
- 批准号:
9765382 - 财政年份:2018
- 资助金额:
$ 75.02万 - 项目类别:
Targeting glutamate carboxypeptidase in perinatal brain injury
靶向谷氨酸羧肽酶在围产期脑损伤中的作用
- 批准号:
9263554 - 财政年份:2016
- 资助金额:
$ 75.02万 - 项目类别:
Targeting glutamate carboxypeptidase in perinatal brain injury
靶向谷氨酸羧肽酶在围产期脑损伤中的作用
- 批准号:
10631173 - 财政年份:2016
- 资助金额:
$ 75.02万 - 项目类别:
Targeting glutamate carboxypeptidase in perinatal brain injury
靶向谷氨酸羧肽酶在围产期脑损伤中的作用
- 批准号:
10530903 - 财政年份:2016
- 资助金额:
$ 75.02万 - 项目类别:
Targeting glutamate carboxypeptidase in perinatal brain injury
靶向谷氨酸羧肽酶在围产期脑损伤中的作用
- 批准号:
9923754 - 财政年份:2016
- 资助金额:
$ 75.02万 - 项目类别:
Targeting glutamate carboxypeptidase in perinatal brain injury
靶向谷氨酸羧肽酶在围产期脑损伤中的作用
- 批准号:
9346116 - 财政年份:2016
- 资助金额:
$ 75.02万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 75.02万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 75.02万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 75.02万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 75.02万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 75.02万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 75.02万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 75.02万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 75.02万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 75.02万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 75.02万 - 项目类别:
Research Grant